O-002Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe

Introduction: mPAC remains associated with poor outcomes. While new compounds/combinations continue to be explored, treatment options are still limited. Data on systemic treatment choices in mPAC and outcomes outside clinical trials are scarce. The goal of this pan-European project was to generate data on diagnosis, treatment patterns and outcomes from the records of patients who completed first-line mPAC treatment across Europe.